Lorlatinib and alectinib are both targeted therapies used in the treatment of non-small cell lung cancer (NSCLC). These medications, specifically designed for patients with anaplastic lymphoma kinase (ALK) rearrangements, have shown significant efficacy in recent clinical trials. This article aims to provide a comprehensive comparison of lorlatinib and alectinib, highlighting their mechanisms...